Marvel Biosciences Announces Proposed Convertible Debenture Offering

Marvel announced a non‑brokered private placement of up to $500,000 in unsecured convertible debentures bearing 12 % annual interest, maturing 31 Dec 2027. The debentures convert at $0.12 per share (holder’s option) and are subject to forced conversion if the TSX‑V price stays ≥ $0.60 for ten consecutive days. Proceeds will fund drug formulation, toxicology studies, and general working capital. No commission or finder's fees are payable.

• Size vs balance sheet: $500k is modest relative to total liabilities of ~$4.3 M (2025‑12‑31) but adds a high‑cost 12 % debt instrument that will increase interest expense ($60k p.a.) and dilute shareholders if conversion occurs.
• Capital efficiency: The company already raised non‑dilutive cash from grants (~$1.2 M) and strategic partners (5 Horizons, NRC IRAP). This financing is a fallback to cover near‑term working‑capital needs for formulation and toxicology work—activities already budgeted in prior announcements.
• Market perception: The conversion price ($0.12) is above the current trading level (~$0.17) but well below the forced‑conversion trigger ($0.60). Investors are unlikely to see immediate dilution, making the news routine rather than a surprise catalyst.
• Risk profile: Adds leverage and future dilution risk, slightly negative on a risk‑averse basis, yet provides needed cash without further equity issuance—overall net effect is modestly positive for liquidity but not material to valuation.

Marvel Biosciences focuses on neurodevelopmental disorders using MB‑204, a fluorinated derivative of the FDA‑approved adenosine A₂A antagonist istradefylline. MB‑204 targets autism spectrum disorder, Rett syndrome, Fragile X, and depression. The program has progressed through cGMP synthesis, GLP toxicology, and now seeks Phase I human trials (Q2 2026).